by: Parent Project Muscular Dystrophy
Edgewise Therapeutics recently joined PPMD for a webinar to provide the Becker community information about the company’s clinical trials for Becker.
Edgewise’s Chief Scientific Officer and Chief Medical Officer, shared two year results from the completed Phase 1 ARCH study in adults with Becker and more information about their current enrolling trial, GRAND CANYON, a phase 2 pivotal cohort for adults living with Becker. Additionally, the webinar provides updates on the trial’s progress and what participants can expect during the study. The session also includes a Q&A portion where Edgewise addresses questions from the community about the trials and potential outcomes.
